Stereotaxis Inc. Reports Q3 Loss, Tops Revenue Estimates
LUCD Stock | USD 0.84 0.01 1.18% |
About 61% of Lucid Diagnostics' investor base is looking to short. The analysis of overall sentiment of trading Lucid Diagnostics stock suggests that many investors are alarmed at this time. The current market sentiment, together with Lucid Diagnostics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lucid Diagnostics stock news signals to limit their universe of possible portfolio assets.
Lucid |
Stereotaxis delivered earnings and revenue surprises of -60 percent and 35.24, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock
Read at zacks.com
Lucid Diagnostics Fundamental Analysis
We analyze Lucid Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Lucid Diagnostics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Lucid Diagnostics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lucid Diagnostics stock to make a market-neutral strategy. Peer analysis of Lucid Diagnostics could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics with similar companies.
Peers
Lucid Diagnostics Related Equities
XAIR | Beyond Air | 13.51 | ||||
KIDS | Orthopediatrics Corp | 2.37 | ||||
FNA | Paragon 28 | 2.06 | ||||
CVRX | CVRx | 1.85 | ||||
IRMD | Iradimed | 1.39 | ||||
OFIX | Orthofix Medical | 1.12 | ||||
LIVN | LivaNova PLC | 0.67 | ||||
SRDX | SurModics | 0.66 | ||||
CLPT | Clearpoint Neuro | 0.53 | ||||
NPCE | Neuropace | 0.50 | ||||
ELMD | Electromed | 0.38 | ||||
ITGR | Integer Holdings | 0.31 | ||||
NARI | Inari Medical | 0.19 | ||||
LUNG | Pulmonx Corp | 2.19 |
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |